Human growth hormone (GH1) gene polymorphism map in a normal-statured adult population by Esteban, Cristina et al.
 Clinical Endocrinology (2007) 
 
66
 
, 258–268 doi: 10.1111/j.1365-2265.2006.02718.x
© 2006 The Authors
 
258
 
Journal compilation © 2006 Blackwell Publishing Ltd
 
O R I G I N A L  A R T I C L E
 
Blackwell Publishing Ltd
Human growth hormone (
 
GH1
 
) gene polymorphism map in a 
normal-statured adult population
 
Cristina Esteban*, Laura Audí*, Antonio Carrascosa*, Mónica Fernández-Cancio, Annalisa Pérez-Arroyo, 
Angels Ulied, Pilar Andaluz, Rosa Arjona, Marian Albisu, María Clemente, Miquel Gussinyé and 
Diego Yeste
 
Departments of Pediatrics and Pediatric Endocrinology and Nutrition Research Unit, Hospital Materno-infantil Vall d’Hebron, 
Autonomous University of Barcelona, Barcelona, Spain 
 
Summary
 
Objective
 
GH1
 
 gene presents a complex map of single nucleotide
polymorphisms (SNPs) in the entire promoter, coding and noncoding
regions. The aim of the study was to establish the complete map of
 
GH1
 
 gene SNPs in our control normal population and to analyse its
association with adult height.
 
Design, subjects and measurements
 
A systematic 
 
GH1
 
 gene
analysis was designed in a control population of 307 adults of both
sexes with height normally distributed within normal range for the
same population: 
 
−
 
2 standard deviation scores (SDS) to +2 SDS. An
analysis was performed on individual and combined genotype
associations with adult height.
 
Results
 
Twenty-five SNPs presented a frequency over 1%: 11 in the
promoter (P1 to P11), three in the 5
 
′
 
UTR region (P12 to P14), one
in exon 1 (P15), three in intron 1 (P16 to P18), two in intron 2 (P19
and P20), two in exon 4 (P21 and P22) and three in intron 4 (P23
to P25). Twenty-nine additional changes with frequencies under 1%
were found in 29 subjects. P8, P19, P20 and P25 had not been
previously described. P6, P12, P17 and P25 accounted for 6·2% of
the variation in adult height (
 
P =
 
 0·0007) in this population with
genotypes A/G at P6, G/G at P6 and A/G at P12 decreasing height
SDS (
 
−
 
0·063 
 
±
 
 0·031, 
 
−
 
0·693 
 
±
 
 0·350 and 
 
−
 
0·489 
 
±
 
 0·265, Mean 
 
±
 
 SE)
and genotypes A/T at P17 and T/G at P25 increasing height SDS
(+1·094 
 
±
 
 0·456 and +1·184 
 
±
 
 0·432).
 
Conclusions
 
This study established the 
 
GH1
 
 gene sequence
variation map in a normal adult height control population confirming
the high density of SNPs in a 
 
relatively
 
 small gene. Our study shows
that the more frequent SNPs did not significantly contribute to
height determination, while only one promoter and two intronic
SNPs contributed significantly to it. Studies in larger populations will
have to confirm the associations and 
 
in vitro
 
 functional studies will
elucidate the mechanisms involved. Systematic 
 
GH1
 
 gene analysis
in patients with growth delay and suspected GH deficiency/
insufficiency will clarify whether different SNP frequencies and/
or the presence of different sequence changes may be associated with
phenotypes in them.
(Received 6 March 2006; returned for revision 16 June 2006; finally 
 
revised 5 September 2006; accepted 10 September 2006)
 
Introduction
 
Human skeletal growth and final height attainment are a result of
a multifactorial regulation involving systemic and local hormones,
growth and nutritional factors, lifestyle and genetic factors. Heritability
estimates
 
1
 
 and genome-wide linkage analysis
 
2
 
 have shown that
genetic factors play a major role in determining stature. Among these
factors, the GH-IGF-I axis plays an important role during postnatal
life, and associations between structural variations in its genes and
height are currently under study.
 
3
 
 Although growth hormone (GH)
deficiency is a well-known cause of growth retardation, which
responds to GH replacement therapy, the diagnosis and physio-
pathological mechanisms for the so-called ‘idiopathic isolated GH
deficiency’ (IIGHD) require further clarification. In addition, GH
secretion levels and markers of GH biological activity have been
demonstrated to be specific and sensitive only in major deficiency
states.
 
4,5
 
 Genetic causes of GH deficiency within the 
 
GH1
 
 gene have
been established; however, they are rarely recognized and only
sought in major GH deficiency states during childhood and in family
studies.
 
3
 
 
 
GH1
 
 gene, located at 17q22–24, is a component of the
GH gene cluster in which five genes evolving from a common
ancestor are 91–99% sequence conserved (paralogues).
 
6
 
 
 
GH1
 
 is more
abundantly expressed in pituitary cells, while the other four genes
are expressed in placental tissue. Large deletions within the 
 
GH1
 
 gene
cluster were described first followed by point mutations, the majority
of which affect introns 3 or 4, provoke skipping of exon 3 product
and exert a dominant effect.
 
3,7,8
 
 More recently, the presence of single
nucleotide polymorphic points (SNPs) in the promoter region or in
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intron 4 of the 
 
GH1
 
 gene have been described
 
9–12
 
 and associations
with promoter allele activities or with GH secretion efficacy and
circulating IGF-I levels in growth-retarded patients have also been
described.
 
11,12
 
 Other studies have analysed several 
 
GH1
 
 gene SNP
genotypes as related to the incidence of neoplasia, with a positive
association with colorectal neoplasia for intron 4 SNP,
 
13
 
 a negative
result for breast carcinoma
 
14,15
 
 or a positive one for breast cancer
risk.
 
16,17
 
 In addition, a recent study in a cohort of adults over ages
60 years detected a significant association between genotypes at one
SNP in the 
 
GH1
 
 gene promoter region and at the intron 4 SNP
described by Hasegawa 
 
et al
 
.
 
11
 
 with baseline bone density and
accelerated bone loss together with an interaction with weight at
1 year.
 
18
 
 Intron 4 SNP described by Hasegawa 
 
et al
 
.
 
11
 
 has also been
associated, in women, with shorter body height and reduced
mortality,
 
19
 
 whereas another intron 4 SNP (T1169A) has been
associated in both sexes with a favourable metabolic profile.
 
20
 
A systematic SNP study was conducted by Adkins 
 
et al
 
.
 
21
 
 in 
 
GH1
 
promoter, coding and noncoding regions in DNAs from placental
tissues, and analysis of associations between genotypes and birth
weight revealed an association between an alternate nucleotide
at 
 
−
 
1 and +3 of translation initiation site and fetal growth restriction.
However, no systematic 
 
GH1
 
 gene analysis in the entire promoter,
coding and noncoding regions has been conducted in adults to
establish the map of structural variation and its possible association
with height. The relatively short size of the entire gene permits a
complete analysis which is, nevertheless, hampered by the need to
avoid amplification of any other of the GH cluster genes (paralogues)
and the high density of sequence variations.
To obtain normative data for subsequent analysis of 
 
GH1
 
 gene
contribution to IIGHD in children, a systematic 
 
GH1
 
 gene structural
analysis was designed in a normal adult control population to
establish the 
 
GH1
 
 gene SNP map in adults from our population with
heights within the normal range, determine the genotype frequencies
and analyse possible associations between individual and combined
SNPs with height.
 
Subjects and methods
 
Subjects
 
A total of 307 adult subjects of both sexes (164 women and 143 men)
were recruited from hospital personnel and parents of patients with
no history of growth retardation. Subjects had to fulfil the following
criteria: Iberian Peninsular (except Basque) family origin and no
family history of pathological short stature. A single subject per
family was included. The protocol was approved by the Hospital Vall
d’Hebron Ethics Committee and written informed consent was
obtained from each participant. Height standard deviation scores
(height SDS) were calculated according to sex-specific reference
growth charts for the Spanish population (Carrascosa 
 
et al
 
.
 
22
 
 charts
were used for subjects under ages 30 years and Hernández 
 
et al
 
.
 
23
 
 for
subjects aged 30–50 years). Only individuals with height SDS
between 
 
−
 
2 and +2 SDS were included in the study (mean 
 
−
 
0·016;
32 women and 28 men between 
 
−
 
2·000 and 
 
−
 
1·010; 99 women and
80 men between 
 
−
 
1·000 and +0·910; 33 women and 35 men between
+1·010 and +1·980) and sample size was adjusted for normal sex and
height SDS distribution. Height and weight were recorded in the
morning by a single observer. Height was measured with a
Harpenden stadiometer. Four millilitres of peripheral venous
blood were drawn into EDTA-containing tubes for molecular
genetic analysis.
 
Genomic DNA study
 
Genomic DNA was obtained from peripheral blood following the
method described by Lahiri and Nurnberger.
 
24
 
 DNA was amplified
by polymerase chain reaction (PCR) using a nested strategy. Briefly,
50 ng of genomic DNA were added to a 10 
 
µ
 
l reaction mixture
of 1 m
 

 
 Mg(OAc)
 
2
 
, 0·6 m
 

 
 dNTPs, 0·3 
 
µ
 

 
 of each primer, and
0·4 U 
 
r Tth
 
 DNA polymerase XL (Applied Biosystems, Foster City,
CA, USA). The sense and antisense primers used corresponded
to nucleotides 4156–5
 
′
 
ACGGTCCGCCACTACGCCCAGC-3
 
′
 
 and
the complement of 6948–5
 
′
 
TGCAGTGAGCCAAGATTGTGCC-3
 
′
 
of the GH gene cluster.
 
6
 
 The PCR reaction mix was denatured
for 5 min at 94 
 
°
 
C and cycled 40 times (94 
 
°
 
C, 1 min; 72 
 
°
 
C, 3 min
30 s) followed by a 7-min extension at 72 
 
°
 
C. The resulting 
 
GH1
 
PCR products (2893 bp) were used as templates for five nested
reactions (AN, BL, CK, DI, FP), carried out as follows: 1 
 
µ
 
l of
each 
 
GH1
 
 PCR product was added to a 20 
 
µ
 
l reaction mixture
of 1·5 m
 

 
 MgCl
 
2
 
, 0·2 m
 

 
 dNTPs, 0·3 
 
µ
 

 
 of each primer and
0·4 U Eco Taq DNA polymerase (Ecogen S.R.L., Barcelona, Spain).
Reaction mixtures were denatured for 5 min at 94 
 
°
 
C, cycled 40
times (94 
 
°
 
C, 1 min; 58 
 
°
 
C, 1 min; and 72 
 
°
 
C, 1 min), followed
by a 7-min extension at 72 
 
°
 
C. Sense and antisense primers were
as follows:
sense A: 4573–5
 
′
 
AAGGGGAGAGCAAAGTGTGG3
 
′;
 
antisense N: 5068–5
 
′
 
TGACGGGCTTGTGCTAAT3
 
′;
 
sense B: 4983–5
 
′
 
GGGAAGGGAAAGATGACAAG3
 
′;
 
antisense L: 5583–5
 
′
 
GGATAAGGGAATGGTTGG3
 
′;
 
sense C: 5469–5
 
′
 
TCTGTTGCCCTCTGGTTTC3
 
′;
 
antisense K: 6157–5
 
′
 
GGCGAAGACACTCCTGAG3
 
′;
 
sense D: 5843–5
 
′
 
TGGTGGGCGGTCCTTCTC3
 
′;
 
antisense I: 6601–5
 
′
 
AGCCCGTAGTTCTTGAGTAG3
 
′;
 
sense F: 6229–5
 
′
 
AACGCTGATGGGGGTGAGG3
 
′;
 
antisense P: 6748–5
 
′
 
GGTGGGCACTGGAGTGGCAA3
 
′;
 
Sequencing from both ends was performed by the dideoxy
method using ABI PRISM BigDye Terminator version 3·1 Cycle
Sequencing Kit (Applied Biosystems, Foster City, CA, USA). 
 
GH1
 
gene nucleotide sequence published by Chen 
 
et al
 
.
 
6
 
 was used as control.
For each DNA, the five segments from the nested PCR were assembled
with the SeqEscape programme (Applied Biosystems) and interpreta-
tion was made visually and simultaneously by two observers. Antisense
sequencing was performed to confirm each nucleotide sequence
change up to the establishment of the more frequent SNP map (fre-
quency over 1%), whereas less frequent single or multiple nucleotide
changes were reconfirmed in each DNA by antisense sequence and
resequencing after a new nested PCR from original DNA was performed.
 
Single nucleotide polymorphism (SNP) genotyping
 
The sequences for the five genes of the GH cluster identified by Chen
 
et al
 
.
 
6
 
 and reported as the GI sequence 183148 were aligned using
 260
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the Multalin program.
 
25
 
 SNPs and other sequence changes identified
were indicated using their position corresponding to 
 
GH1
 
. Genotypes
were deduced by the combination of genetic variation at the
polymorphic positions.
 
Statistical analysis
Standardized height was investigated for normal distribution
(Kolmogorov-Smirnov test: c2 = 2·882, P = 0·4733). Hardy–
Weinberg equilibrium was tested for SNPs presenting three alternate
genotypes according to standard procedures using χ2-analysis.
 test was applied to investigate individual and combined SNP
association with adult height SDS; significance assessment was
adjusted for multiple testing using Fisher’s PLSD test setting
Pcritical = 0·05 or the Bonferroni–Dunn test setting Pcritical = 0·05/n
(n = number of comparisons carried out). Stepwise regression
analysis was applied to predict the contribution of SNPs to adult
height SDS. Statview 4·5 program (Abacus Concepts Inc., Berkeley,
CA, USA) was used for statistical analyses.
Results
GH1 gene sequence variation
GH1 gene sequence comparison with the GI-183148 sequence
published by Chen et al.6 yielded a total of 54 single or multiple
nucleotide changes. Twenty-five SNPs presented a frequency over 1%
(genotypes and frequencies are listed in Table 1). SNPs which
presented the three alternate genotypes (P2 to P4, P6, P7, P10 and
P24) were in Hardy–Weinberg equilibrium (data not shown). Twenty-
nine additional changes were found with a frequency under 1%
or involving more than one nucleotide and thus could be considered
as rare variant SNPs (R1 to R29) (Table 2). These changes were
found in 29 of 307 subjects (9·4%), all in heterozygosity.
GH1-paralogue alignment
A sequence alignment was performed to study possible sequence
recombinations among paralogues of the five GH1-gene cluster
Table 1. Frequencies of genotypes at SNPs in the GH1 gene
Position†
Functional 
region‡ Location§ Nucleotide¶
Percentage (%)
Homozygous 
GI 183148 Heterozygous
Homozygous 
alternative
P1 = 4825* Promoter G-del 95·1 4·9 0
P2 = 4856* Promoter T-G 5·2 32·9 61·9
P3 = 4863* Promoter T-G 5·2 32·6 62·2
P4 = 4886 Promoter G-T 31·6 50·8 17·6
P5 = 4996 Promoter T-C 97·1 2·9 0
P6 = 5089 Pit 1p RE Promoter A-G 72·6 24·4 3·0
P7 = 5107* VDR/RA/T3 RE Promoter G-T 39·7 48·9 11·4
P8 = 5116 VDR/RA/T3 RE Promoter G-A 98·7 1·3 0
P9 = 5131 TATA box Promoter G-del 84·1 14·0 1·9
P10 = 5157 Promoter A-G 27·7 49·8 22·5
P11 = 5162 Promoter A-T-C 81·4 16·9 (AT)/0·9 (AC) 0·6 (TT)
P12 = 5178 5′UTR A-G 94·1 5·9 0
P13 = 5187 5′UTR A-C 94·8 5·2 0
P14 = 5221* 5′UTR G-T 0 6·5 93·5
P15 = 5231 Thr 3 Ala/Pro Exon I A-G-C 96·4 3·3 (AG)/0·3 (AC) 0
P16 = 5286 Intron I A-G 98·1 1·9 0
P17 = 5290 Intron I A-T 98·4 1·6 0
P18 = 5443 Intron I T-C 94·5 5·5 0
P19 = 5681 Intron II A-T 98·1 1·9 0
P20 = 5686 Intron II G-A 98·3 1·7 0
P21 = 6191* Val 110 Ile Exon IV G-A 98·4 1·6 0
P22 = 6232* Thr 123 Exon IV G-A 97·1 2·9 0
P23 = 6263* Intron IV C-T 95·8 3·9 0·3
P24 = 6331* Intron IV T-A 27·7 54·4 17·9
P25 = 6358 Intron IV T-G 98·1 1·9 0
†SNPs are identified correlatively from P1 to P25 with corresponding numbering to Genebank accession GI 183148.
‡Response elements previously reported in the GH1 promoter region included in SNPs. Three SNPs are located in codons.
§Gene region location.
¶Nucleotides found at this position.
*In these positions, the less represented alleles do not correspond to any other paralogue of the GH1 gene.
Allelic frequencies in bold: < 1% found in an SNP position.
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(Fig. 1). This alignment showed that 9 of 25 SNPs (36%) in the GH1
gene did not correspond to any of the paralogues.
Among the 29 rare SNPs found, six (20·7%) did not correspond
to any of the paralogues: two were located in the 5′UTR region (R9
and R10), two in intron 1 (positions 5300 = R14 and 5302 = R17),
one in intron 2 (position 5679 = R21) and one in intron 4 (position
6344 = R23) (Table 2).
Equivalence with previously reported GH1 changes
Equivalence with changes and SNPs previously reported by other
authors are shown in Table 3. The majority found a high density of
SNPs in the promoter and 5′UTR regions in control populations.10,12,21
Several sequence changes have been reported in patients with
familial or idiopathic short stature,11,26,27 whereas P8, P19, P20 and
P25 (at positions 5165, 5681, 5686 and 6358, respectively, in the
Genebank accession GI 183148) located in the promoter, intron 2
and intron 4 regions, respectively, had not been previously described.
GH1 genotypes and associations with height SDS
Associations between genotypes and standardized height were first
studied in the subpopulation of 278 controls carrying only the 25
most frequent SNPs in the GH1 gene (c2 = 2·59; P = 0·5458 for
normality of height distribution).
Three individual SNPs showed a statistically significant association
with height SDS: at positions 5286 (P16), 5290 (P17) and 6358 (P25).
Subjects with heterozygous genotypes presented statistically significant
taller stature than the corresponding homozygous genotypes
(P = 0·016 for P16, P = 0·015 for P17 and P = 0·023 for P25)
Table 2. GH1 additional sequence changes
Genotype Position* Location† GH1 paralogues‡ n§ Height SDS¶
1 R1 = 4688 G > A Promoter CS5/GH2 2 1·080/1·520
2 R2 = 4903 G > C + R3 = 4907 C > A Promoter CS5 1 1·870
3 R4 = 4979 C > T Promoter GH2/CS1/CS2 1 −1·780
4 R5 = 5003 C > T + R6 = 5078 T > G Promoter GH2 1 −1·100
5 R7 = 5111–5125 CAGTGGGGAGAAGG
> GCAGGGAGAGAGAACT
Promoter (VDR/RA/T3 RE) CS1/CS2 1 0·640
6 R8 = 5124–5125 GG > CT Promoter (VDR/RA/T3 RE) CS1/CS2 1 0·179
7 R9 = 5122 delA + R10 = 5123–5125
AGG > GAACT
Promoter (VDR/RA/T3 RE) NO 1 0·200
8 5162 A > C (P11) + R11 = 5165 G > C 5′UTR CS5 2 −1·260/−0·40
9 5162 A > C (P11) + 5165 G > C (R11) 5′UTR + Intron I CS5 1 −0·510
+ R12 = 5266 T > C
10 R13 = 5220 C > T + 5231 A > C (P15) 5′UTR + Exon I (Thr3Pro) CS1 1 0·400
11 R14 = 5300 G > T Intron I NO 1 −1·560
12 5300 G > T (R14) + (R15 = 6056 A  
> C + R16 = 6061 C > G)
Intron I + Intron III NO + GH2/CS1/CS2/CS5 1 −1·930
13 R17 = 5302 G > A Intron I NO 1 −0·300
14 R18 = 5354 G > C + [6056 A > C (R15) Intron I + Intron III GH2/CS1/CS2/CS5 1 0·060
+ 6061 C > G (R16)]
15 R19 = 5406 InsGA Intron I GH2/CS1/CS2/CS5 1 0·400
16 R20 = 5481 T > C Intron I CS1/CS2/CS5 1 −0·750
17 R21 = 5679 G > C Intron II NO 3 −0·690/ 
−0·160/1·350
18 6056 A > C (R15) + 6061 C > G (R16) Intron III GH2/CS1/CS2/CS5 1 0·057
19 R22 = 6190 C > T Exon IV (Asn109) CS1/CS2/CS5 1 1·060
20 R23 = 6344 C > T Intron IV NO 2 0·120/1·500
21 R24 = 6453 A > G Intron IV GH2/CS1/CS2/CS5 1 −0·260
22 R25 = 6514 C > A + R26 = 6517G > T Exon V (Pro133Hys  
+ Arg134Leu)
CS5 1 −0·026
23 R27 = 6653 C > G Exon V (Ile179Met) CS1/CS2/CS5 1 −0·350
24 R28 = 6671 G > A + R29 = 6677 C > T Exon V (Val 185 + Gly 187) CS2 1 0·640
*Nucleotide changes found in less than 1% of controls with numbers corresponding to Genebank accession GI 183148.
†Gene region location: response elements, codons and predicted amino acids affected are highlighted.
‡GH1 gene paralogues corresponding to the nucleotide changes found. NO means that the nucleotide found does not correspond to any of the of GH1 
paralogues.
§n = number of controls.
¶Height SDS corresponding to each control bearing the sequence change.
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Fig. 1 Alignment of GH gene cluster paralogues (GH1, GH2, CS5, CS1 and CS2) from Genebank accession sequence GI 183148. The SNPs (P1 to P25) identified in the population, as well as 28 additional 
sequence changes, are signalled with their corresponding number. Segment of the GH1 sequence translocated by CS1/CS2 (box); segments where GH1 and paralogues differ (in red); the STOP codon is marked.
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(Fig. 2a,b,c). P16 and P17 were in linkage disequilibrium (LD)
(r2 = 0·831), while P25 was carried by six subjects homozygous at
P16 and P17.
GH1 gene genotypes were defined by genetic variation in the 25
polymorphic positions. We found 163 different combinations. Only
two genotypes presented a frequency over 5% (Table 4). Height SDS
in the two more frequent genotypes did not differ significantly and
covered the whole height range. Genotype 1 presented four hetero-
zygous variations and Genotype 2 was the corresponding homozygous
genotype. Heterozygous positions corresponded to SNPs with the
highest frequency variation (4886 (P4), 5107 (P7), 5157 (P10) and
6331 (P24)). In addition, DNAs exhibited a different genotype in
each of 129 subjects (46·4%).
The 11 SNPs found in the promoter region (Table 1) were grouped
in 94 genotypes and analysed for association with adult height SDS.
The four more frequent combinations are listed in Table 4: height
SDS of these four genotypes did not differ statistically although
Genotype 3 tended to have a shorter height. Genotype 3 differed
from Genotype 1 in the SNP located at position 5089 (P6),
corresponding to Pit 1 proximal responsive element for GH1 gene
promoter. Genotype 4 is heterozygous at positions 4856 (P2), 4863
(P3) and 5107 (P7). In addition, 19% of cases exhibited a genotype
in the promoter region carried by only one subject.
Combination of the three SNPs in the 5′UTR region of GH1 gene
resulted in five different genotypes. SNPs at positions 5178 (P12) and
5187 (P13) were in LD (r2 = 0·88). Mean height SDS comparison
among these genotypes was not statistically significant, although
mean height SDS of alternate nucleotide carriers at position 5178
(P12) tended to be shorter (Table 4).
An  analysis was conducted to investigate the interaction
between two or more SNPs and height SDS. SNPs at positions 5286
(P16) and 5290 (P17) were in LD (r2 = 0·83): the heterozygous
genotype AG/AT for these SNPs was associated with taller stature
(shown above). SNP at position 6358 (P25) increased the expected
height SDS for individual carriers of the G allele at 5089 (P6) SNP
as shown in Fig. 2(d): subjects heterozygous at 6358 (P25) were taller
Table 3. Location of GH1 gene polymorphisms or mutations in previously reported and present study
Present study
Position 
GI 183148
Wagner 
1997 (10)
Giordano 
1997 (9)
Hasegawa 
2000 (11)
Horan 
2003 (12)
Millar 
2003 (26)
Lewis 
2004 (27)
Adkins 
2005 (21)
ENTREZ
SNP
4688 (R1) −476
P1 = 4825 −400 −339
P2 = 4856 −369 −308 −308
P3 = 4863 −362 −301 −301 rs2011732
P4 = 4886 −339 P2 −278 −278 rs2005171
P5 = 4996 −229 −168 −168 rs2727338
P6 = 5089 −139 −75 −75 −75 rs11568828
P7 = 5107 −118 −57 P3 −57 −57 rs2005172
P8 = 5116
5124–5125 (R8) −40_−39 del GG
ins CT 
P9 = 5131 −93/4 −31 −31 rs11568827
P10 = 5157 −68 −6 −6 −6 rs6171
P11 = 5162 −63 −1 −1 −1 rs695
5165 (R11) +3 +3 +3 rs6175
P12 = 5178 −47 +16 +16 +16 rs9282699
P13 = 5187 −38 +25 +25 +25 rs6172
P14 = 5221 −4 +59 +59 +59 rs6173
P15 = 5231 Thr 3 Ala +69 rs2001314
5266 (R12) rs9282698
P16 = 5286 +124
P17 = 5290 +128
5300 (R14) +76
5302 (R17) +140
5354 (R18) rs2001344
P18 = 5443 +219 +281 rs3744287
P19 = 5681
P20 = 5686
P21 = 6191 Val 110 Ile rs5388
P24 = 6331 P1 +1070 rs2665802
P25 = 6358
6653 (R27) Ile179Met
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than the mean, and mean height SDS of subjects with GG/TG
combined genotype was significantly higher than the corresponding
GG/TT genotype (P = 0·0021), suggesting an interaction between
these two SNPs as they were not in LD.
Analysis of height SDS association with the most frequent single
and combined SNPs and with rare variant SNPs was performed in
the 29 individuals carrying the rare SNPs (Table 2). None of them
carried any of the three SNPs (P16, P17 and P25) related to taller
stature in the population of 278 controls with only the frequent
SNPs. In these 29, mean height SDS (0·000 ± 0·987, from −1·930 to
+1·870) did not differ from that of the 278 controls (−0·018 ± 1·041,
from −2·000 to +1·980). Analysis of associations between individual
SNP genotypes and height SDS revealed that SNPs at positions 5089
(P6), 5178 (P12) and 5187 (P13) were associated with significantly
shorter stature (Fig. 2e). Only two sequence changes considered as
rare SNPs were carried by individuals in the lower normal height
range (between −1·500 and −2·000 SDS) (Table 2): R4 (4979 C > T)
in the promoter region and R14 (5300 C > T) in intron 1. Predicted
single amino acid changes located in exon 5 (R25 to R27) were not
associated with short stature.
In the entire population of 307 controls, stepwise regression
analysis between height SDS and genotypes at the 25 SNPs showed
that genotypes at 5089 (P6), 5178 (P12), 5290 (P17) and 6358 (P25)
were significantly correlated with height SDS (r2 = 0·062, P = 0·0007)
with genotypes A/G at P6, G/G at P6 and A/G at P12 decreasing
height SDS (−0·063 ± 0·031, −0·693 ± 0·350 and −0·489 ± 0·265,
respectively, Mean ± SE) and genotypes A/T at P17 and T/G at
P25 increasing height SDS (+ 1·094 ± 0·456 and +1·184 ± 0·432,
respectively).
Discussion
Genetic variations within human GH1 gene have been described by
several authors.9–12,21 The populations described to date comprised
small numbers of normal-stature individuals,9 male adults with
narrow height range12 or growth-retarded patients with/without
GHD before achievement of adult height.9,11,12 Our study was
designed to characterize the GH1 gene sequence variation in
individuals within the whole range of normal adult height (between
−2 and +2 SDS) according to the standards for our population.
Height was normally distributed, both sexes were equally represented
and the GI-183148 homozygous sequence6 was used for comparison.
A nested PCR with specific primers for GH1 gene was designed, thus
avoiding amplification of any other GH gene paralogue of the GH
gene cluster.
Our results establish a map of 25 SNPs as present in over 1% of
individuals, whereas 29 other sequence changes (single or multiple
nucleotide) are present in less than 1% of subjects. More than 50%
(n = 14) of SNPs are located in the promoter and 5′UTR regions,
thus confirming previous reports: Giordano et al.9 reported eight
Fig. 2  (a), (b), (c) Box plot distribution of height SDS in normal adult height population bearing the most frequent SNPs in the GH1 gene (n = 278) according 
to genotypes in 5286 (P16), 5290 (P17) and 6358 (P25). SNPs P16 and P17 are in LD (r2 = 0·83). SNP P25 is carried in heterozygosis by six subjects homozygous 
at P16 and P17. Carriers of any of these polymorphisms in heterozygosis have significantly taller stature (P = 0·016 for P16, P = 0·015 for P17 and P = 0·023 
for P25; Bonferroni–Dunn test). (d) Box plot distribution of height SDS in normal adult height population bearing the most frequent SNPs in the GH1 gene 
(n = 278) according to their combined genotypes at SNPs 5089 (P6) and 6358 (P25). Subjects heterozygous T/G at P25 are taller than subjects with the same 
corresponding genotype at P6. Height SDS differed significantly between genotypes GG/TT and GG/TG (P = 0·0021; Bonferroni–Dunn test). (e) Box plot 
distribution of height SDS in normal adult height population bearing additional SNPs in the GH1 gene with frequencies < 1% (n = 29) according to their 
genotypes at SNPs 5089 (P6), 5178 (P12) and 5187 (P13). Subjects carriers of heterozygous AG at P6 and/or P12 and P13 are significantly shorter than 
homozygous AA (P = 0·014; Bonferroni–Dunn test).
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SNPs in the promoter and 5′UTR regions, Wagner et al.10 16 SNPs
from the promoter to intron 1 and Horan et al.12 identified 36
haplotypes in control subjects of the British population, which
would result from the combination of 15 of the previously reported
SNPs. Our results confirm the presence of 13 of those points; SNP
at 5165 (R11 in the present study and +3 in references9,12) was present
in less than 1% of subjects and a new SNP is described (P8 at 5116
in the VDR/RA/T3 responsive element sequence). The remaining
Table 4. GH1 more frequent genotypes in the control population bearing only 25 SNPs (n = 278)
GH1 genotypes at the 25 SNPs
Genotype
GH1 gene region Height SDS 
Promoter region 5′UTR Translatable region + Introns Mean SD n % (over 278)
1 GG/GG/GG/GT/TT/AA/GT/GG/GG/AG/AA AA/AA/TT AA/AA/AA/TT/AA/GG/GG/GG/CC
/TA/TT 
−0·006 1·148 22 7·9
2 GG/GG/GG/GG/TT/AA/TT/GG/GG/AA/AA AA/AA/TT AA/AA/AA/TT/AA/GG/GG/GG/
CC/TT/TT 
0·043 1·031 21 7·5
GH1 genotypes defined by genetic variation at the 25 polymorphic positions present in > 1% of the population.
Genotype 1 presented four heterozygous positions (bold) corresponding to SNPs: P4, P7, P10 and P24 as shown in Table 1. These positions presented the 
highest allelic variation.
Genotype 2 was homozygous at all 25 SNPs.
Mean height SDS comparison between Genotypes 1 and 2 was not statistically significant.
GH1 genotypes in the promoter region 
SNP position in GI 183148 Height SDS 
Genotype
4825
(P1)
4856
(P2)
4863
(P3)
4886
(P4)
4996
(P5)
5089
(P6)
5107
(P7)
5116
(P8)
5131
(P9)
5157
(P10)
5162
(P11) Mean SD Minimum Maximum n
% (over 
278)
1 GG GG GG GT TT AA GT GG GG AG AA −0·105 1·139 −2·000 1·980 35 12·6
2 GG GG GG GG TT AA TT GG GG AA AA 0·055 0·995 −1·760 1·480 25 9·0
3 GG GG GG GT TT AG GT GG GG AG AA −0·495 0·835 −1·630 1·800 17 6·1
4 GG TG TG GG TT AA GT GG GG AA AA 0·008 1·070 −1·530 1·350 15 5·4
Combined single genotypes 53 19·1
Other combinations 133 47·8
GH1 genotypes defined by genetic variation at 11 polymorphic positions in the promoter region in controls with 25 SNPs (n = 278).
Four genotypes had a frequency > 5%.
Heterozygous alleles (in bold).
Genotypes 1 and 2 corresponded to the more frequent complete GH1 genotypes.
Genotype 3 differed from Genotype 1 in SNP at position 5089 (P6) (underlined).
Genotype 4 is heterozygous at positions 4856 (P2), 4863 (P3) and 5107 (P7).
GH1 genotypes in the 5′UTR region 
SNP position in GI 183148 Height SDS 
Genotype
5178
(P12)
5187
(P13)
5221
(P14) Mean SD Minimum Maximum n % (over 278)
1 AA AA TT −0·010 1·045 −2·000 1·980 250 89·9
2 AA AA GT 0·142 0·977 −1·180 1·350 14 5·1
3 AG AC TT −0·177 1·145 −1·980 1·480 11 4·0
4 AG AA TT −0·830 0·240 −1·000 −0·660 2 0·7
5 AG AC GT −0·810 1 0·3
GH1 genotypes defined by genetic variation at the polymorphic positions in the 5′UTR.
SNPs at positions 5178 (P12) and 5187 (P13) were 85% associated. SNP at position 5221 (P14) was independent.
Mean height SDS comparison was not statistically significant.
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SNPs (from P15 to P25, n = 11) are distributed in introns 1, 2 and
4, and among coding regions only exon 1 and exon 4 bear a total of
three SNPs, two of which predict an amino acid change (P15 and
P21). These two latter SNPs had been described by Millar et al.26 and
the more frequent SNP in intron 4 (P24) has been described by
Hasegawa et al.11 together with the two more frequent SNPs in the
promoter region (P4 and P7 in our map). Three new SNPs are
described (P19 and P20 in intron 2 and P25 in intron 4), all outside
the splice sites. Only SNPs presenting high frequency are present in
homozygous alternate state and this accounts mostly for the majority
of the promoter and 5′UTR SNPs and in the intron 4 more frequent
SNP (P24) described by Hasegawa et al.11 In conclusion, in the entire
coding and noncoding GH1 gene sequence, only P24 is present in
homozygous alternate state. Our results show that the GI 183148
homozygous sequence is present in our population except for SNP
P14 in the 5′UTR region which is only present as the alternate nucleotide
in homozygous or heterozygous states.
As described by several authors9,10,12,21 several promoter SNPs
affected functional sequences and P6 is located in the Pit 1 proximal
responsive element, P7 and P8 in the VDR/RA/T3 responsive
element and P9 (G del) in the TATA box.
The mechanisms by which the high density of SNPs in the GH1
gene is generated has been proposed to be recombination and gene
conversion with any other(s) of the GH cluster genes.9,12,28 Alignment
of the 25 SNPs with the other GH1 gene paralogues demonstrated
in our results that this mechanism is possible for 64% of SNPs.
Familial SNP transmission pattern analysis will be of interest to
support the hypothesis of GH gene recombination.
In addition, 29 of 307 individuals (9·4%) bore additional GH1
sequence changes with frequencies under 1%. As for SNPs, they are
located along the whole gene with higher density in the promoter
and 5′UTR regions. Interestingly, intron 3 and exon 5 present several
of these less frequent changes. Intron 3 has been shown to carry the
majority of single nucleotide mutations causing the dominant form
of GH deficiency.3 The two single nucleotide changes detected in
intron 3 (R15 at 6056 and R16 at 6061) are in perfect LD (r2 = 1·0)
and located within the enhancer splice site element (ESE) described
by Ryther et al.29,30 Studies in additional normal or growth-retarded
populations will permit description of their possible clinical impli-
cations. Five single nucleotide changes are located in exon 5; of these
five, three predict an amino acid change, and one of the three
(Ile179Met) has been described by Lewis et al.27 in a paediatric
patient with familial short stature and the other two, as yet undescribed,
are contiguous in a single individual (Pro133Hys and Arg134Leu).
Polynucleotide changes are mostly located in the promoter region
corresponding to the VDR/RA/T3 response element. As for frequent
SNPs, the majority of the sequence changes with frequencies under
1% may have been generated by recombination within the GH gene
cluster as 19 of 24 (79%) may correspond to one or more of the GH1
gene paralogues.
Our results now show the diversity and complexity of SNP
genotypes, as previously highlighted by other authors9,10,12,21 in a
normal adult height control population. Our initial aim when
designing the present study was to establish the map of GH1 gene
SNPs in our adult control population with heights normally distributed
within the entire normal range for further comparison with
genotypes in our paediatric population with growth delay, variable
response to GH secretion tests and adequate response to GH therapy.
Analysis of SNP association with adult height was subsequently
performed to establish a body of knowledge useful for comparing
patient genotypes and phenotypes. This analysis was first performed
in controls bearing only frequent SNPs (90·5% of the total population).
We demonstrate that the four SNPs with the highest allelic variation
frequencies (P4, P7, P10 and P24) do not significantly contribute to
adult height determination, with the heterozygous genotype being
the most frequent followed by the corresponding homozygous
genotype in the whole sequence, and heights are normally distributed
over the entire height range. The third most frequent combined
genotype in the promoter region in our population presented, in
addition, in heterozygosity, the SNP at P6 in the sequence regulated
by Pit 1 and although mean height of individuals (6·1%) bearing this
genotype was around −0·5 SDS, this was not statistically significant.
Analysis of single SNP genotype association with adult height
yielded few clues as to the contribution of GH1 gene variation to
adult height determination. Only three SNPs (P16, P17 and P25),
present with low frequency and only in heterozygous state, were
individually significantly associated with taller stature and none was
individually associated with shorter stature. P16 and P17 (in LD,
r2 = 0·83) are located in intron 1 and P25 in intron 4. The resulting
sequence for the presence of P16 and P17 corresponded to the
paralogue GH2 and generated a responsive element for a core-
binding protein (Matinspector Programme, Geometrix Software
GmbH, München, Germany) with three Kruppel-type zinc fingers
which could increase the efficacy of GH1 gene transcription;31,32
moreover, Kruppel-like proteins have recently been described in the
brain.33 Stepwise regression analysis demonstrated that P17 and P25
contribute, separately, to an increase of almost 1·0 height SDS. P16
and P17 had been described by Adkins et al.21 although they found
no association with fetal growth, whereas P25 had not previously
been described. The mechanisms by which they may determine taller
final height should be established by in vitro studies analysing GH1
gene transcription and GH protein translation efficiencies.
Analysis of interaction effect between SNPs detected that variation
at P25 masked an effect of P6. Individuals homozygous at P25 (TT)
present a significant association between P6 genotype and height
with the homozygous alternate genotype at P6 (GG) being associated
with shorter stature. This was further confirmed in the subpopulation
of 29 individuals bearing rare SNPs who, in the absence of hetero-
zygous change at P25, presented significantly shorter stature in the
heterozygous alternate nucleotide change at P6 (AG). P6, located at
Pit 1 proximal responsive element of the GH1 gene promoter, was
first described by Wagner et al.10 and Giordano et al.9 and further by
Horan et al.12 Six of nine GH1 gene promoter haplotypes bearing
the alternate G at P6 presented lower transcriptional activities and
electrophoretic mobility shift assays (EMSA) detected differential
protein binding strength, although in vitro studies were unable to
identify this SNP as a major determinant of GH1 gene expression
level.12 A recent study from Giordano et al.34 has shown a twofold
reduced luciferase activity for the G nucleotide bearing promoter
haplotype in transfected rat pituitary cells. Genotypes at P6 had also
been associated with decreased breast cancer risk through its association
with lower GH secretion and IGF-I circulating levels.16,17
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In our results, GH1 gene polymorphic structural variation
accounted for only 6·2% of adult height determination in the entire
adult population studied and genome-wide linkage analysis of
stature in multiple populations revealed no linkage with chromosome
17 GH gene cluster.2,35 As only some of the less frequent SNPs are
statistically associated with height, and in view of the high density
of SNPs, our study may be hampered by selection bias36 and would
ideally have required a wider sampling of some 2 000 individuals;
however, this was a highly laborious strategy when the complete
sequencing technique is applied. The high density of SNPs and their
proximity hamper other genotyping strategies for rapid determination
of the complete GH1 SNP map in large control and patient popu-
lations. Individual SNP associations with height or other GH
secretion-related phenotypic traits will require further confirmation
by studies in larger populations and by in vitro functional studies.
In conclusion, our study established the GH1 gene sequence
variation map in an adult control population with heights normally
distributed within the normal range. SNPs and other sequence
change contributions to skeletal growth as observed at adult
height demonstrated that, despite the high frequency of variation
and diversity and complexity of combinations, only some of the less
frequent SNPs were associated with taller stature (P17 in intron 1
and P25 in intron 4), even masking the SNP contribution to a shorter
one (P6 in the promoter and P12 in the 5′UTR regions, respectively).
Systematic GH1 gene analysis in patients with growth delay and
suspected GH deficiency/insufficiency will clarify whether different
SNP frequencies and/or the presence of different sequence changes
may be associated with phenotypes in them.
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